STAAR Surgical EBITDA 2010-2025 | STAA
STAAR Surgical ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
STAAR Surgical Annual EBITDA
(Millions of US $) |
| 2024 |
$-7 |
| 2023 |
$31 |
| 2022 |
$47 |
| 2021 |
$37 |
| 2020 |
$10 |
| 2019 |
$16 |
| 2018 |
$9 |
| 2017 |
$0 |
| 2016 |
$-10 |
| 2015 |
$-3 |
| 2014 |
$-6 |
| 2013 |
$3 |
| 2012 |
$1 |
| 2011 |
$5 |
| 2010 |
$0 |
| 2009 |
$-1 |
STAAR Surgical Quarterly EBITDA
(Millions of US $) |
| 2025-03-31 |
$-55 |
| 2024-12-31 |
$-26 |
| 2024-09-30 |
$7 |
| 2024-06-30 |
$13 |
| 2024-03-31 |
$-1 |
| 2023-12-31 |
$11 |
| 2023-09-30 |
$7 |
| 2023-06-30 |
$9 |
| 2023-03-31 |
$3 |
| 2022-12-31 |
$1 |
| 2022-09-30 |
$14 |
| 2022-06-30 |
$18 |
| 2022-03-31 |
$13 |
| 2021-12-31 |
$8 |
| 2021-09-30 |
$9 |
| 2021-06-30 |
$12 |
| 2021-03-31 |
$8 |
| 2020-12-31 |
$5 |
| 2020-09-30 |
$6 |
| 2020-06-30 |
$0 |
| 2020-03-31 |
$0 |
| 2019-12-31 |
$3 |
| 2019-09-30 |
$4 |
| 2019-06-30 |
$5 |
| 2019-03-31 |
$3 |
| 2018-12-31 |
$2 |
| 2018-09-30 |
$2 |
| 2018-06-30 |
$4 |
| 2018-03-31 |
$1 |
| 2017-12-31 |
$0 |
| 2017-09-30 |
$2 |
| 2017-06-30 |
$0 |
| 2017-03-31 |
$-1 |
| 2016-12-31 |
$2 |
| 2016-09-30 |
$-1 |
| 2016-06-30 |
$-1 |
| 2016-03-31 |
$-9 |
| 2015-12-31 |
$1 |
| 2015-09-30 |
$-1 |
| 2015-06-30 |
$-1 |
| 2015-03-31 |
$-1 |
| 2014-12-31 |
$-3 |
| 2014-09-30 |
$-1 |
| 2014-06-30 |
$-1 |
| 2014-03-31 |
$-1 |
| 2013-12-31 |
$-1 |
| 2013-09-30 |
$1 |
| 2013-06-30 |
$1 |
| 2013-03-31 |
$2 |
| 2012-12-31 |
$-1 |
| 2012-09-30 |
$0 |
| 2012-06-30 |
$0 |
| 2012-03-31 |
$1 |
| 2011-12-31 |
$1 |
| 2011-09-30 |
$1 |
| 2011-06-30 |
$2 |
| 2011-03-31 |
$1 |
| 2010-12-31 |
$0 |
| 2010-09-30 |
$-1 |
| 2010-06-30 |
$0 |
| 2010-03-31 |
$1 |
| 2009-12-31 |
$1 |
| 2009-09-30 |
$0 |
| 2009-06-30 |
$0 |
| 2009-03-31 |
$-1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$0.882B |
$0.314B |
|
Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma.
|
